Cargando…
The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients
We presented the rationale for the use of thymosin α1 as prophylaxis of severe COVID-19 in cancer patients undergoing active treatment, constituting the background for the PROTHYMOS study, a prospective, multicenter, open-label, Phase II randomized study, currently in its start-up phase (Eudract no....
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Medicine Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874885/ https://www.ncbi.nlm.nih.gov/pubmed/33538178 http://dx.doi.org/10.2217/fon-2020-0754 |